Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease.


Journal

Translational neurodegeneration
ISSN: 2047-9158
Titre abrégé: Transl Neurodegener
Pays: England
ID NLM: 101591861

Informations de publication

Date de publication:
08 06 2021
Historique:
received: 30 03 2021
accepted: 27 05 2021
entrez: 8 6 2021
pubmed: 9 6 2021
medline: 21 12 2021
Statut: epublish

Résumé

The aggregation of amyloid β (Aβ) is central in the pathogenesis of Alzheimer's disease (AD). Recently it has been shown that specifically, larger, Thioflavin T-binding Aβ aggregates are associated with increased neuroinflammation and cytokine release. This study was aimed to quantify fibrillary amyloid aggregates, so-called nanoplaques, and investigate their relationship with cytokines in the cerebrospinal fluid (CSF). CSF was collected from 111 patients assessed for cognitive complaints at the Oslo University Hospital Memory Clinic. The patients were grouped based on their amyloid status. The CSF nanoplaque concentration was quantified with the Thioflavin T-fluorescence correlation spectroscopy (ThT-FCS) assay. The levels of nine cytokines (eotaxin-1, granulocyte stimulating factor, interleukin [IL]-6, IL-7, IL-8, monocyte chemoattractant protein-1, gamma-induced protein 10, macrophage inflammatory protein [MIP]-1α, and MIP-1β) were quantified with a magnetic bead-based multiplex assay and read on a Luminex IS 200 instrument. There were 49 amyloid-negative and 62 amyloid-positive patients in the cohort; none of the cytokines differed significantly between the amyloid groups. The increased nanoplaque levels were associated with levels of MIP-1β below the lower limit of quantification, and with decreased levels of MIP-1α and IL-8. The associations remained significant when adjusted for age, sex, cognitive function, apolipoprotein ε4 status and CSF core biomarker levels. The cytokine levels were not associated with amyloid status in this cohort. The nanoplaque levels were negatively associated with MIP-1β, MIP-1α and IL-8, which is in line with recent findings suggesting that the upregulation of some cytokine markers has a protective role and is negatively associated with AD progression.

Sections du résumé

BACKGROUND
The aggregation of amyloid β (Aβ) is central in the pathogenesis of Alzheimer's disease (AD). Recently it has been shown that specifically, larger, Thioflavin T-binding Aβ aggregates are associated with increased neuroinflammation and cytokine release. This study was aimed to quantify fibrillary amyloid aggregates, so-called nanoplaques, and investigate their relationship with cytokines in the cerebrospinal fluid (CSF).
METHODS
CSF was collected from 111 patients assessed for cognitive complaints at the Oslo University Hospital Memory Clinic. The patients were grouped based on their amyloid status. The CSF nanoplaque concentration was quantified with the Thioflavin T-fluorescence correlation spectroscopy (ThT-FCS) assay. The levels of nine cytokines (eotaxin-1, granulocyte stimulating factor, interleukin [IL]-6, IL-7, IL-8, monocyte chemoattractant protein-1, gamma-induced protein 10, macrophage inflammatory protein [MIP]-1α, and MIP-1β) were quantified with a magnetic bead-based multiplex assay and read on a Luminex IS 200 instrument.
RESULTS
There were 49 amyloid-negative and 62 amyloid-positive patients in the cohort; none of the cytokines differed significantly between the amyloid groups. The increased nanoplaque levels were associated with levels of MIP-1β below the lower limit of quantification, and with decreased levels of MIP-1α and IL-8. The associations remained significant when adjusted for age, sex, cognitive function, apolipoprotein ε4 status and CSF core biomarker levels.
CONCLUSION
The cytokine levels were not associated with amyloid status in this cohort. The nanoplaque levels were negatively associated with MIP-1β, MIP-1α and IL-8, which is in line with recent findings suggesting that the upregulation of some cytokine markers has a protective role and is negatively associated with AD progression.

Identifiants

pubmed: 34099032
doi: 10.1186/s40035-021-00244-3
pii: 10.1186/s40035-021-00244-3
pmc: PMC8186140
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
Cytokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Subventions

Organisme : Stiftelsen för Strategisk Forskning
ID : SBE13-0115
Organisme : Vetenskapsrådet
ID : VR 2018-05337
Organisme : Stiftelsen Olle Engkvist Byggmästare
ID : 199-0480
Organisme : Magnus Bergvalls Stiftelse (SE)
ID : 2018-02642
Organisme : Region Stockholm
ID : ALF project 20180365
Organisme : Region Stockholm
ID : ALF project 20190561

Références

Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Neurobiol Aging. 2007 Apr;28(4):485-96
pubmed: 16600437
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
J Neuroinflammation. 2005 Oct 07;2:22
pubmed: 16212664
Neurodegener Dis. 2007;4(1):13-27
pubmed: 17429215
Neurobiol Aging. 2019 Apr;76:125-132
pubmed: 30711675
Acta Neuropathol Commun. 2019 Jul 26;7(1):120
pubmed: 31349874
Brain. 2015 Oct;138(Pt 10):2814-33
pubmed: 26283673
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Tidsskr Nor Laegeforen. 2011 Nov 15;131(22):2254-7
pubmed: 22085955
Arch Neurol. 2010 Jun;67(6):746-9
pubmed: 20558394
Neurobiol Dis. 2001 Dec;8(6):1057-68
pubmed: 11741401
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Biochemistry. 2015 Dec 15;54(49):7203-11
pubmed: 26574169
Front Immunol. 2018 Sep 19;9:2122
pubmed: 30283455
J Geriatr Psychiatry Neurol. 2006 Jun;19(2):114-7
pubmed: 16690997
J Neurol Neurosurg Psychiatry. 2019 May;90(5):590-598
pubmed: 30630955
Neurology. 2018 Aug 28;91(9):e867-e877
pubmed: 30054439
J Clin Invest. 2005 Aug;115(8):2083-98
pubmed: 16007267
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Front Cell Neurosci. 2018 Aug 03;12:230
pubmed: 30123110
J Alzheimers Dis. 2020;73(4):1615-1626
pubmed: 31958095
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Mol Neurobiol. 2014 Oct;50(2):534-44
pubmed: 24567119
Pharmaceuticals (Basel). 2020 Sep 02;13(9):
pubmed: 32887304
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18176-81
pubmed: 19011092
R Soc Open Sci. 2017 Jan 4;4(1):160696
pubmed: 28280572
J Neuroimmunol. 2000 Aug 1;108(1-2):227-35
pubmed: 10900358
Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18
pubmed: 24632990
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2103-10
pubmed: 19838705
Neurosci Lett. 2005 Jul 22-29;383(1-2):12-6
pubmed: 15936505
J Intern Med. 2015 Sep;278(3):277-90
pubmed: 25752192
J Neurol Sci. 2006 Nov 15;249(2):110-4
pubmed: 16843497
Neuro Oncol. 2005 Apr;7(2):122-33
pubmed: 15831231
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
J Alzheimers Dis. 2018;62(1):385-397
pubmed: 29439331
Ann Transl Med. 2015 Jun;3(10):136
pubmed: 26207229
J Alzheimers Dis. 2018;62(4):1595-1607
pubmed: 29504529
Aging Cell. 2020 Nov;19(11):e13258
pubmed: 33155752
J Exp Med. 2003 Jun 16;197(12):1657-66
pubmed: 12796468
J Alzheimers Dis. 2020;77(2):831-842
pubmed: 32741818
J Neurol Sci. 2017 May 15;376:242-254
pubmed: 28431620
BMC Neurol. 2016 Sep 26;16(1):185
pubmed: 27671345
J Neuroinflammation. 2020 May 6;17(1):151
pubmed: 32375809
J Alzheimers Dis. 2007 Jul;11(4):447-55
pubmed: 17656823
J Neurochem. 2000 Nov;75(5):1898-906
pubmed: 11032879
J Alzheimers Dis. 2019;68(2):571-582
pubmed: 30814355
Nat Neurosci. 2018 Oct;21(10):1332-1340
pubmed: 30250260
Brain. 2017 Mar 1;140(3):792-803
pubmed: 28122877
Nucl Med Commun. 2017 Mar;38(3):234-241
pubmed: 27984539
J Alzheimers Dis. 2020;76(2):681-689
pubmed: 32538836
J Cereb Blood Flow Metab. 1997 Mar;17(3):280-9
pubmed: 9119901
Nat Commun. 2019 Apr 4;10(1):1541
pubmed: 30948723
J Biol Chem. 2011 Apr 22;286(16):13827-33
pubmed: 21349839
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1218-27
pubmed: 27016501
Front Cell Neurosci. 2021 Jan 18;14:618986
pubmed: 33536876
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Aging Cell. 2017 Feb;16(1):27-38
pubmed: 27723233
Immunology. 2014 Apr;141(4):549-63
pubmed: 24224652
Front Aging Neurosci. 2021 Jan 08;12:608628
pubmed: 33488383
Int J Neurosci. 2008 Dec;118(12):1659-72
pubmed: 18937113

Auteurs

Mari Aksnes (M)

Department of Geriatric Medicine, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. mari.aksnes@medisin.uio.no.

Hans Christian D Aass (HCD)

Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.

Ann Tiiman (A)

Department of Clinical Neurosciences (CNS), Center for Molecular Medicine CMM L8:01, Karolinska Institutet, Stockholm, Sweden.

Trine Holt Edwin (TH)

Department of Geriatric Medicine, The Memory Clinic, Oslo University Hospital, Oslo, Norway.
Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Lars Terenius (L)

Department of Clinical Neurosciences (CNS), Center for Molecular Medicine CMM L8:01, Karolinska Institutet, Stockholm, Sweden.

Nenad Bogdanović (N)

Department of Neurobiology, Care Science and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden.

Vladana Vukojević (V)

Department of Clinical Neurosciences (CNS), Center for Molecular Medicine CMM L8:01, Karolinska Institutet, Stockholm, Sweden.

Anne-Brita Knapskog (AB)

Department of Geriatric Medicine, The Memory Clinic, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH